News | Atrial Fibrillation | September 08, 2021

Continuous Heart Rhythm Monitoring and Anticoagulation Does Not Prevent Stroke

LOOP study presented in a Hot Line Session at 2021 ESC Congress

The Medtronic Linq II implantable cardiac monitor.

The Medtronic Linq II implantable cardiac monitor.


September 8, 2021 — Continuous heart rhythm monitoring – with anticoagulation if atrial fibrillation is detected – does not prevent strokes in those at risk. That was the finding of late breaking LOOP Study presented in a Hot Line session today at European Society of Cardiology (ESC) Congress 20211 and published in the Lancet.[1]

Atrial fibrillation is the most common heart rhythm disorder, affecting more than 33 million people worldwide.[2] The disorder increases the risk of stroke by five-fold, but this risk can be reduced with anticoagulation treatment.[3] The LOOP study was initiated because patients with atrial fibrillation are often asymptomatic and thus remain undiagnosed and untreated. 

The study investigated whether continuous electrocardiogram (ECG) monitoring using an implantable loop recorder, and subsequent anticoagulation if atrial fibrillation was detected, would reduce the risk of stroke or systemic arterial embolism in patients at risk.

“In a population of high-risk patients, atrial fibrillation was detected and treated much more often in those undergoing ECG monitoring. We found a non-significant 20% reduction in risk of stroke which was not accompanied by a similar reduction in cardiovascular mortality," explained principal investigator Professor Jesper Hastrup Svendsen of Copenhagen University Hospital - Rigshospitalet, Denmark. "More studies are needed but our findings may suggest that not all atrial fibrillation is worth screening for, and not all screen-detected atrial fibrillation merits anticoagulation.”

Danish national registries were used to identify individuals from the general population aged 70 years or older with at least one of the following additional stroke risk factors: hypertension, diabetes, heart failure or previous stroke. The exclusion criteria included any history of atrial fibrillation, currently using oral anticoagulation, a contraindication to oral anticoagulation, or a cardiac implantable electronic device (CIED).

Participants were randomized in a 1:3 ratio to receive continuous ECG monitoring or standard care. Those in the monitoring group had an implantable loop recorder (Medtronic Reveal Linq) inserted under the skin on the left side of the chest under local anesthesia. The device continuously (24/7) recorded the heart’s electrical activity. Every night, any ECGs indicating heart rhythm abnormalities (such as atrial fibrillation) were transferred remotely to a server for evaluation by clinicians. If atrial fibrillation lasting more than six minutes was diagnosed, patients were advised to start oral anticoagulation. The standard care group had a telephone consultation with a nurse once a year. The primary outcome was time to the combined endpoint of stroke or systemic arterial embolism.

A total of 6,004 participants were randomised: 1,501 to monitoring and 4,503 to standard care. The mean age was 74.7 years and 47.3% were women. The median duration of monitoring was 39.3 months, and the median follow-up period was 64.5 months.

Participants in the monitoring group were more likely to have atrial fibrillation detected and to start oral anticoagulation compared to those receiving standard care. Atrial fibrillation was diagnosed in 477 participants (31.8%) in the monitoring group and 550 (12.2%) in the control group (hazard ratio [HR] 3.17; 95% confidence interval [CI] 2.81–3.59; p<0.001). Oral anticoagulation was initiated in 445 participants (29.7%) in the monitoring group and 591 (13.1%) in the control group (HR 2.72; 95% CI 2.41–3.08; p<0.001).

The primary outcome occurred in 318 participants, including 67 (4.5%) in the monitoring group (0.88 events per 100 person-years; 95% CI 0.68–1.12) and 251 (5.6%) in the control group (1.09 events per 100 person-years; 95% CI 0.96–1.24). There was no significant difference between the two groups (HR 0.80; 95% CI 0.61–1.05; p=0.11).

Cardiovascular death occurred in 43 participants (2.9%) in the monitoring group versus 157 (3.5%) in the control group (HR 0.83; 95% CI 0.59–1.16; p=0.27), and death from any cause occurred in 168 participants (11.2%) in the monitoring group versus 507 (11.3%) in the control group (HR 1.00; 95% CI 0.84–1.19; p=1.00).

Funding for the LOOP Study is supported by The Innovation Fund Denmark [12-135225], The Research Foundation for the Capital Region of Denmark [no grant number], The Danish Heart Foundation [11-04-R83-A3363-22625], Aalborg University Talent Management Program [no grant number], Arvid Nilssons Fond [no grant number], Skibsreder Per Henriksen, R. og Hustrus Fond [no grant number], Læge Sophus Carl Emil Friis og hustru Olga Doris Friis’ Legat [no grant number], and an unrestricted grant from Medtronic [no grant number].

Professor Svendsen is a member of Medtronic advisory boards and has received speaker honoraria and research grants from Medtronic in relation to this work and outside this work.

Find more ESC Hot Line late-breaking study news

 

References:

1. Jesper H Svendsen, Søren Z Diederichsen, Søren Højberg, Derk W Krieger, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. The Lancet. Published:August 29, 2021DOI:https://doi.org/10.1016/S0140-6736(21)01698-6.

2. Rahman F, Kwan GF, Benjamin EJ, et al. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2014;11:639–654.

3. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42:373–498.

Related Content

News | Antiplatelet and Anticoagulation Therapies
October 4, 2021 — One month of dual antiplatelet therapy (DAPT) following stent implantation in high bleeding risk ...
Home October 04, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 — The STOPDAPT-2 ACS trial does not support the use of one month of dual antiplatelet therapy (DAPT) ...

Home September 01, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart ...

Home September 01, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

June 21, 2021 — The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's dabigatran etexilate ...

Home June 21, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in ...

Home May 15, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term, dual-antiplatelet ...

Home April 28, 2021
Home
Feature | Antiplatelet and Anticoagulation Therapies | By Dave Fornell, Editor

A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal ...

Home March 22, 2021
Home
Videos | Antiplatelet and Anticoagulation Therapies

The COMPARE CRUSH Trial looked at the effect of per-hospital crushed prasugrel tablets in patients with STEMI planned ...

Home October 19, 2020
Home
Videos | Antiplatelet and Anticoagulation Therapies

Roxana Mehran, M.D., and Marco Valgimiggle, M.D., present the results of the Xience 90/28 trials that evaluated the use ...

Home October 19, 2020
Home
Videos | Antiplatelet and Anticoagulation Therapies

Gregg Stone, M.D., presents the results of a pooled analysis of randomized trials of bivalirudin virus heparin in acute ...

Home October 17, 2020
Home
Subscribe Now